ST Pharm

CompanySouth Korea

ST Pharm develops one asset, in phase 2 (STP0404 in HIV-1 infection). Mostly small molecule; based in South Korea.

1
Asset
Furthest stage
Phase 2
0
Trials
1
Signal

Pipeline

1
  • STP0404

    Allosterically inhibits HIV-1 integrase, disrupting viral maturation and replication.

    Phase 2, Small molecule, HIV-1 infection

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals1
  • Similar companies2

Intelligence